Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement
21 août 2023 14h37 HE
|
Psyence Group Inc.
TORONTO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement
02 août 2023 10h34 HE
|
Psyence Group Inc.
VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural...
Psyence Group Corporate Update
12 juil. 2023 07h00 HE
|
Psyence Group Inc.
Highlights: Drug development, Phase IIb clinical trial advanced planning underway in AustraliaPsyence granted worldwide licensing agreement to commercialize Filament’s PEX010 (25 mg) in...
Psyence Appoints Intellectual Property Expert to Its Board of Directors
11 juil. 2023 07h00 HE
|
Psyence Group Inc.
TORONTO, July 11, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce the appointment of Christopher Bull to the board of...
Psyence Group Announces Closing of Fourth Tranche of Private Placement and Conversion of Convertible Debt Note
03 avr. 2023 14h44 HE
|
Psyence Group Inc.
TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Psyence Group inc. (CSE:PSYG | OTCQB:PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics...
Psyence Group Announces Cantheon Capital Private Placement
23 mars 2023 07h00 HE
|
Psyence Group Inc.
VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental...
Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia
21 mars 2023 07h00 HE
|
Psyence Group Inc.
VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental...
Psyence and Eden Labs Announce Extraction and Product Development Collaboration
24 janv. 2023 07h00 HE
|
Psyence Group Inc.
TORONTO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG. |. OTCQB: PSYGF) (Psyence or the Company), a life science biotechnology company pioneering the use of natural psychedelics...
Psyence Group Completes Export of Pharma Grade Psilocybin Extract to UK
20 janv. 2023 07h00 HE
|
Psyence Group Inc.
TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce that it has exported purified pharmaceutical grade...
Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp
09 janv. 2023 17h47 HE
|
Psyence Group Inc.
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental...